Abstract
To the Editor: Recently, Sobol et al. (April 30 issue)1 studied the expression of myeloid antigen in adult acute lymphoblastic leukemia (ALL). Surprisingly, patients who were positive for the antigen (My+) accounted for 33 percent of the series, being positive for MCS-2 (CD13), MY9 (CD33), or both. I would like to comment on some points.To include My+ cases that are negative for B-cell and T-cell markers and showed germ-line configurations of immunoglobulin and T-cell receptor genes as "pure myeloid-antigen phenotypes" in a group with ALL is a rather uncommon practice. Not surprisingly, none of these patients had a . . .